ClinicalTrials.gg
RecruitingNCT07260071HIYA-PKDUpdated Nov 4, 2026

Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease

An observational study in Autosomal Dominant Polycystic Kidney Disease (ADPKD, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by King's College London · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
200
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Polycystic Kidney, Autosomal Dominant with a site in United Kingdom — 4 open to participants now, 7 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United Kingdom.

Started
2025
with 2 others
Observational
6 of 20
2 open now
Registered
20th of 20
by date
Lead sponsor
1 of 20
King's College London

Among the 20 studies in Polycystic Kidney, Autosomal Dominant with a site in United Kingdom, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 20th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

4 of the 20 studies in Polycystic Kidney, Autosomal Dominant with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Polycystic Kidney, Autosomal Dominant with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance imaging (MRI) for rapid diagnosis alongside genetic testing. The main question it aims to answer is:

What is the prevalence of hypertension in a population sample of adolescents with ADPKD?

Participants will have the following measurements performed:

  • Height and weight.
  • Blood pressure.
  • Non-invasive measurement of arterial stiffness.
  • Cardiac and renal MRI.
  • Blood sample.
  • Genetic testing.
Read the detailed description

INTRODUCTION Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the commonest genetic cause of chronic kidney disease. Despite being inherited, most people do not get symptoms until adulthood with mean age of chronic renal failure around 53 years. Hence, it was thought that there is no need to screen children and young people (C\&YP) at risk of ADPKD until old enough to understand and agree to testing. Linked to this, imaging criteria to diagnose ADPKD mostly cover adult ages.

The validity of this 'adults only' approach is challenged by reports of hypertension in C\&YP with ADPKD, affecting up to a quarter by late teens. This is important in deciding whether to change screening policy because early treatment has the potential to reduce risk of cardiovascular events long-term. Death from cardiovascular disease is still a frequent event in ADPKD families, even before reaching end-stage kidney disease. Not only does the renal damage in ADPKD affect BP and cardiovascular health but there is evidence that ADPKD causes generalised endothelial dysfunction. This provides further justification for good BP control and treatment from the earliest stages of ADPKD.

Currently, it is not known whether the estimated prevalence of hypertension in C\&YP with ADPKD is overestimated because most evidence comes from specialist Paediatric Nephrology centres, where it would be expected that the more severe cases would be managed. This study will determine whether blood pressure (BP) should be screened in all C\&YP at risk, as well as testing the utility of ultrasound and genetic approaches.

This proposed study will be most comprehensive assessment of blood pressure in ADPKD across all age groups. As a result, information gained may revolutionise the approach to the measurement and management of BP in medical practice, particularly in children.

PATIENT AND PUBLIC INVOLVEMENT This study has been set up to specifically consider individuals with ADPKD and so the investigators have designed this study in discussion with The PKD Charity. The investigators will continue to utilise this wealth of patient experience as this study is conducted by keeping the PKD Charity informed of progress, presenting results at patient group meetings and conferences, so that patients are able to see the work that the investigators are doing to improve their understanding of ADPKD. Any publications resulting from this work will be sent to the PKD Charity for inclusion on their website.

A trustee of the PKD charity and patient representative for ADPKD has previously reviewed patient information sheets and consent forms and as a result of helpful comments the investigators have modified the patient information sheet for children.

Lastly these proposals have been previewed as a 'theoretical potential study' on the UK PKD Charity forums: no-one expressed concerns over the study design and over 40 responders expressing immediate interest in participating.

PARTICIPANT SELECTION Source of participants

The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C\&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they have to make the first contact to express interest. Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the participant appears to be eligible for the study, the relevant Participant Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. The study coordinator will book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site

Number of participating sites involved: 3

Participant numbers: The study aims to recruit 200 C\&YP in total. This generates a 95% confidence of detecting a difference between populations with hypertension prevalence of 20% (ADPKD) versus 10% with 80% power. Once they have undertaken the full BP and cardiovascular assessment (anticipated over 1-2 visits), participants will only be seen once and will not be required for further follow up. Results of genetic testing are anticipated to be available after 6-12 months.

STUDY PROCEDURES Screening Procedures

Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the subject appears to be eligible for the study, the relevant Patient Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. All participants that undergo screening will be logged onto a screening log associated with the study.

Once eligibility is confirmed, and the participant has received the PIS, the study coordinator will contact them to book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site.

Participant recruitment The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C\&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they now have to make the first contact to express interest.

Participants will be offered reimbursement of their reasonable expenses for them and their parent /guardian to attend their chosen participating site.

Participants and their parent/guardian will be sent age appropriate information sheets prior to their first appointment at the hospital and will have at least a week to consider their participation in the study. Written materials will be produced in English. They will be consented by a clinician when they attend for Visit 1 of the study.

Follow up Procedures When the results of the tests are ready, families will be informed of the results with a telephone consultation. If there is no evidence of ADPKD, hypertension or other novel findings, the participant will be discharged. If there is evidence of ADPKD, hypertension or another medical condition, the participant will be followed up in an NHS clinic as per standard of care.

Radiology Assessments MRI will be used to scan the kidneys for evidence of ADPKD and assess the structure and function of the heart. Both regions will be imaged in the same scan session. No contrast will be required.

MRI safety aspects will be handled by the research MRI staff in the study centre. Experienced MRI radiographers will ensure all participants have completed an MRI safety questionnaire prior to their MRI scan as per the Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use, MHRA, February 2021 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/958486/MRI_guidance_2021-4-03c.pdf.

END OF STUDY DEFINITION

  • The date of when all the samples from all patients have been analysed.

ASSESSMENT OF SAFETY

  • No particular serious adverse events (SAEs) are expected to occur during this study.
  • Where a SAE is related to the study procedures and is an unexpected occurrence (that is, the type of event is not listed in the protocol as an expected occurrence) then it will be reported immediately upon knowledge of the event to R\&D and always within 24 hours. A note will be put in the case report form (CRF) and on the participants medical notes.
  • If a SAE/AE occurs that does not require immediate reporting, this will be reported in the participant's CRF and reported to GSTT when copied into the Annual Progress Report.
  • All serious adverse events that are to be reported to R\&D will be signed and dated and completed by the Investigator.
  • At other sites, the Principal Investigators at all sites must report all SAEs to the Chief Investigator first where possible. The Chief Investigator is then responsible for reporting events to the regulators/R\&D as the sponsor office.

Trial Steering Committee (if applicable) N/A

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD

Keywords

  • hypertension
  • children
  • young people
  • autosomal dominant polycystic kidney disease
  • arterial stiffness
  • genetic testing
  • albuminuria
  • proteinuria
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

General population of children and young people at risk of ADPKD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12 - 17 years at the time of consent
  • Able to tolerate the key study investigations (office blood pressure measurement, ambulatory blood pressure measurement, MRI and blood test)
  • Parent with confirmed clinical diagnosis of ADPKD
  • Parent (if child \<16 years) or both parent and young person (if >=16 years) consents to genetic testing for ADPKD and demonstrates understanding of the implications of this.

Exclusion criteria

Exclusion Criteria:

  • 18 years or above at the time of study entry
  • Unable to tolerate key study investigations
  • Presence of associated co-morbidities which make it difficult to interpret results, including congenital cardiac anomalies and known TSC-PKD1 mutations
  • Unwilling to undergo genetic testing for ADPKD
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • ADPKD positive

    Participants with positive renal MRI and/or genetic test for ADPKD

  • ADPKD negative

    Participants with negative renal MRI and genetic test for ADPKD

06

What researchers measure

Primary outcomes

  1. Number of participants with hypertension in general population of children and young people at risk of ADPKD.

    Diagnosis of hypertension from clinic manual blood pressure and 24 hours ambulatory blood pressure measurement

    Time frame: Day 1

Secondary outcomes

  1. Number of participants diagnosed with ADPKD from renal MRI compared to the number from genetic testing.

    Prevalence of ADPKD assessed by renal MRI compared to genetic testing

    Time frame: Day 1

  2. Number of participants with cyst negative but gene positive ADPKD in this age group.

    Agreement between MRI and genetic testing for diagnosis of ADPKD.

    Time frame: Day 1

  3. Number of participants with abnormal albuminuria in the population at risk of ADPKD.

    Presence of albuminuria in urine samples collected.

    Time frame: Single time point

  4. Central blood pressure in young people with ADPKD compared to healthy controls

    Comparison between central aortic systolic and diastolic pressure (mmHg) measured by tonometry between participants with ADPKD and healthy controls

    Time frame: Day 1

  5. Arterial stiffness in young people with ADPKD compared to healthy controls

    Comparison in carotid-femoral pulse wave velocity (m/s) between participants with ADPKD and healthy controls

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009 Apr;5(4):221-8. doi: 10.1038/nrneph.2009.13. PubMed 19322187 ↗
  • Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009 Jan;20(1):205-12. doi: 10.1681/ASN.2008050507. Epub 2008 Oct 22. PubMed 18945943 ↗
  • Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007 Apr 14;369(9569):1287-1301. doi: 10.1016/S0140-6736(07)60601-1. PubMed 17434405 ↗

Individual participant data

Plan to share: No — IPD will not be shared beyond the study team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Dec 2, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07260071
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Aug 15, 2025
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Benjamin Boxer, PhD
Contact
gstt.hiya.pkd@nhs.net
+44 20 7188 4770
Louise Keehn, MSc
Contact
louise.keehn@kcl.ac.uk
+44 20 7188 4770
Manish Sinha, PhD, MRCP (UK), MRCPCH
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion